Overview

* Lyell Q3 adjusted net loss beats analyst expectations

* Company acquired global rights to LYL273, a GCC-targeted CAR T-cell product

* Initiated PiNACLE - H2H Phase 3 trial for aggressive large B-cell lymphoma

Outlook

* Company expects to begin PiNACLE - H2H trial enrollment by early 2026

* Lyell anticipates LYL273 Phase 1 trial data update in H1 2026

* Current cash expected to support pipeline advancement into 2027

Result Drivers

* LESS R&D EXPENSES: Research and development expenses were $28.2 million for the third quarter ended September 30, 2025, compared to $39.5 million for the same period in 2024.

*

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat -$29.12 -$45.49

Adjusted mln mln (3

Net Analysts

Income )

Q3 Net -$38.85

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Lyell Immunopharma Inc ( LYEL ) is $12.00, about 43.7% below its November 11 closing price of $17.25

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)